Published in AIDS on September 27, 2002
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med (2004) 7.67
HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat (2008) 1.45
Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis (2010) 1.42
Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol (2009) 1.41
Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients. Sci Transl Med (2014) 1.39
Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis (2006) 1.32
HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations. Hepatology (2012) 1.30
Hepatitis C in HIV-infected individuals: cure and control, right now. J Int AIDS Soc (2011) 1.03
Treatment outcomes of treatment-naïve Hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts. PLoS One (2013) 0.99
The management of chronic viral hepatitis: A Canadian consensus conference 2004. Can J Infect Dis Med Microbiol (2004) 0.95
Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus. Eur J Clin Microbiol Infect Dis (2003) 0.93
Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia. PLoS One (2014) 0.88
Treatment of hepatitis C virus infection. World J Gastroenterol (2007) 0.87
Risk Factors and Seroprevalence of Hepatitis C among Patients Hospitalized at Mulago Hospital, Uganda. J Trop Med (2011) 0.83
Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease. Eur J Clin Microbiol Infect Dis (2008) 0.83
Viral factors associated with cytokine expression during HCV/HIV co-infection. J Interferon Cytokine Res (2007) 0.83
Within-host dynamics of the hepatitis C virus quasispecies population in HIV-1/HCV coinfected patients. PLoS One (2011) 0.83
Hepatitis C virus quasispecies in HIV-infected women: role of injecting drug use and highly active antiretroviral therapy (HAART). Hepatology (2007) 0.83
Impact of hepatitis C on HIV progression in adults with alcohol problems. Alcohol Clin Exp Res (2007) 0.82
Update on Hepatitis B and C Coinfection in HIV. Curr Infect Dis Rep (2005) 0.81
Plasma Hepatitis C Virus Viral Load Among Hepatitis C Virus Mono-Infected and HCV/HIV Co-Infected Individuals in Yunnan Province,China. Hepat Mon (2012) 0.80
High rate of seronegative HCV infection in HIV-positive patients. Biomed Rep (2013) 0.79
Multiple pregnancies, hepatitis C, and risk for hepatocellular carcinoma in Egyptian women. BMC Cancer (2014) 0.78
HCV coinfection associated with slower disease progression in HIV-infected former plasma donors naïve to ART. PLoS One (2008) 0.78
Evidence of distinct populations of hepatitis C virus in the liver and plasma of patients co-infected with HIV and HCV. J Med Virol (2014) 0.78
The association of human immunodeficiency virus infection with spontaneously resolved hepatitis C virus infection and level of viremia among injection drug users. Dig Dis Sci (2007) 0.78
Dissociation of serum and liver hepatitis C virus RNA levels in patients coinfected with human immunodeficiency virus and treated with antiretroviral drugs. J Clin Microbiol (2004) 0.76
Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals. Open Forum Infect Dis (2015) 0.75
The hepatitis C virus 5'UTR genomic region remains highly conserved under HAART: a 4- to 8-year longitudinal study from HCV/HIV co-infected patients. AIDS Res Hum Retroviruses (2010) 0.75
Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients. Hepatology (2014) 0.75
Triple positivity of HBsAg, anti-HCV antibody, and HIV and their influence on CD4+ lymphocyte levels in the highly HIV infected population of Abeokuta, Nigeria. Afr Health Sci (2015) 0.75
Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes. Pathog Glob Health (2016) 0.75
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med (2004) 7.67
The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (2007) 5.18
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl (2012) 4.65
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology (2007) 3.87
Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int (2011) 3.36
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med (2012) 3.20
A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. N Engl J Med (2015) 2.77
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS (2003) 2.66
Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis (2011) 2.60
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis (2010) 2.45
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med (2005) 2.26
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS (2003) 2.20
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 1.94
Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood (2002) 1.94
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis (2008) 1.91
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis (2007) 1.89
Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care (2010) 1.86
Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS (2010) 1.83
Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection--The Hawaii Aging with HIV Cohort. J Neurovirol (2006) 1.76
Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J Immunol (2004) 1.75
End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood (2002) 1.73
Circulating proviral HIV DNA and HIV-associated dementia. AIDS (2005) 1.68
Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr (2004) 1.65
GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype. J Infect Dis (2006) 1.64
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62
Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. J Infect Dis (2006) 1.57
Clinical validation of the NeuroScreen. J Neurovirol (2005) 1.57
Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis (2011) 1.53
Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis (2010) 1.53
Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest (2008) 1.50
Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol (2010) 1.50
Neuropsychological test profile differences between young and old human immunodeficiency virus-positive individuals. J Neurovirol (2007) 1.49
The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology (2006) 1.49
A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine. Antivir Ther (2012) 1.48
CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin Immunol (2003) 1.48
Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. AIDS (2007) 1.45
Trichomonas vaginalis among HIV-Infected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity? Sex Transm Dis (2003) 1.44
Pacific Ocean-wide profile of CYP1A1 expression, stable carbon and nitrogen isotope ratios, and organic contaminant burden in sperm whale skin biopsies. Environ Health Perspect (2010) 1.43
Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial. J Acquir Immune Defic Syndr (2012) 1.38
Women living with human immunodeficiency virus or acquired immunodeficiency syndrome: a global epidemic. Indian J Med Res (2004) 1.38
Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology (2006) 1.38
HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women. Clin Infect Dis (2011) 1.37
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses (2005) 1.37
Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology (2004) 1.36
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology (2006) 1.32
Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS One (2010) 1.30
HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients. PLoS One (2013) 1.27
Cognitive performance related to HIV-1-infected monocytes. J Neuropsychiatry Clin Neurosci (2012) 1.26
The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. AIDS (2005) 1.26
The Effects of Age and HIV on Neuropsychological Performance. J Int Neuropsychol Soc (2010) 1.25
CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol (2002) 1.24
Incidence and characterization of acute HIV-1 infection in a high-risk Thai population. J Acquir Immune Defic Syndr (2008) 1.24
HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS (2011) 1.23
Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology (2005) 1.22
The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr (2007) 1.22
Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res (2009) 1.21
Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cells (2014) 1.20
Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS One (2008) 1.20
Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology (2004) 1.19
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One (2012) 1.19
The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis (2011) 1.17
Aging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapy. J Neurovirol (2008) 1.17
HIV proviral DNA associated with decreased neuropsychological function. J Neuropsychiatry Clin Neurosci (2007) 1.16
Acute hepatitis C virus infection: a chronic problem. Hepatology (2008) 1.15
Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy. J Infect Dis (2004) 1.14
Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr (2003) 1.13
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve (2012) 1.13
Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. J Virol (2007) 1.13
HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease. J Acquir Immune Defic Syndr (2012) 1.12
Recurrent bleeding from peptic ulcer associated with adherent clot: a randomized study comparing endoscopic treatment with medical therapy. Gastrointest Endosc (2002) 1.11
Elevated cervical white blood cell infiltrate is associated with genital HIV detection in a longitudinal cohort of antiretroviral therapy-adherent women. J Infect Dis (2010) 1.10
A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J Immunol (2009) 1.09
HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood (2004) 1.08
Amount of HIV DNA in peripheral blood mononuclear cells is proportional to the severity of HIV-1-associated neurocognitive disorders. J Neuropsychiatry Clin Neurosci (2009) 1.08
HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia. Hepatology (2006) 1.07
Clinical application of polymerase chain reaction to diagnose Clostridium difficile in hospitalized patients with diarrhea. Clin Gastroenterol Hepatol (2004) 1.07
Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study. J Neurovirol (2010) 1.07
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology (2010) 1.07
Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067. J Clin Immunol (2005) 1.06
Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing. Clin Infect Dis (2013) 1.06
A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102. J Acquir Immune Defic Syndr (2006) 1.06
Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci (2010) 1.06
Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials (2003) 1.06
Social stigmatization and hepatitis C virus infection. J Clin Gastroenterol (2006) 1.05
Antibacterial resistance leadership group: open for business. Clin Infect Dis (2014) 1.04
Adipose tissue-derived stem cell-seeded small intestinal submucosa for tunica albuginea grafting and reconstruction. Proc Natl Acad Sci U S A (2012) 1.04
Plasma levels of B-lymphocyte stimulator increase with HIV disease progression. AIDS (2003) 1.04
HIV DNA and dementia in treatment-naïve HIV-1-infected individuals in Bangkok, Thailand. Int J Med Sci (2006) 1.04
Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin Infect Dis (2011) 1.04
The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir. J Clin Pharmacol (2011) 1.04